Abstract:Background Remnant cholesterol (RC) have been suggested as a significant mediator of atherosclerotic cardiovascular diseases. However, the relationship between RC with cause-specific mortality in long-term remained uncertain. This study aimed to investigate the association between time-weighted RC and cause-specific mortality outcomes.Methods This retrospective population-based study enrolled patients attending family medicine clinics in Hong Kong between 1st January 2000, to 31st December 2003 with at least three RC testing results during follow-up. The time-weighted RC was calculated by the products of the sums of two consecutive measurements and the time interval divided by the total time. The primary outcomes were all-cause mortality and cause-specific mortality outcomes. Cox regression and marginal effective plots were applied to identify associations between time-weighted RC and mortality.Results A cohort of 75,342 patients (39.69% males, mean age: 61.3 years old) with at least three valid RC test were included. During up to 19 years of follow-up, in the multivariate model adjusted for demographics, comorbidities, medications, and time-weighted laboratory results, time-weighted RC was associated with all-cause mortality (Hazard ratio [HR]: 1.41; 95% Confidence Interval [CI]: 1.35-1.48) but not RC (HR: 0.99; 95% CI: 0.89-1.10). Time-weighted RC was also associated with increased risks of cardiovascular-related mortality (HR: 1.40; 95% CI: 1.27-1.54), cancer-related mortality (HR: 1.59; 95% CI: 1.43-1.77), and respiratory-related mortality (HR: 1.33; 95% CI: 1.20-1.47). The exploratory analysis of the cause of death demonstrated that time-weighted RC was associated with Ischaemic heart disease, cerebrovascular-related and pneumonia.Conclusions Time-weighted RC was independently associated with all-cause mortality and cause-specific mortality outcomes amongst the general population.### Competing Interest StatementG.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are directly received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871. The remaining authors have no disclosures to report.### Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster (Reference No. UW 20-250).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study were provided by the Hong Kong Hospital Authority, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Hong Kong Hospital Authority.

Remnant cholesterol and all-cause mortality risk: findings from the National Health and Nutrition Examination Survey, 2003-2015

Remnant Cholesterol Predicts Long-term Mortality of Patients with Metabolic Dysfunction-associated Fatty Liver Disease

Remnant Cholesterol Independently Predicts the Development of Nonalcoholic Fatty Liver Disease

Long-term association of remnant cholesterol with all-cause and cardiovascular disease mortality: a nationally representative cohort study

Association of Remnant Cholesterol and Non-High Density Lipoprotein Cholesterol with Risk of Cardiovascular Mortality among US General Population.

Remnant Cholesterol and Severity of Nonalcoholic Fatty Liver Disease.

The Association Between Remnant Cholesterol and All-Cause Mortality and Cardiovascular Mortality Was Modified by Aged in American Adults: a Retrospective Cohort Study

Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis

Remnant cholesterol and mortality in 37.559 patients from LIPIDOGRAM 2004, 2006 and 2015 studies

The Association Between Remnant Cholesterol and the Estimated 10-Year Risk of a First Hard Cardiovascular Event

Remnant Cholesterol and Cardiovascular Mortality in Patients With Type 2 Diabetes and Incident Diabetic Nephropathy

Prognostic value of remnant cholesterol in patients with coronary heart disease: A systematic review and meta-analysis of cohort studies

Associations between remnant cholesterol levels and mortality in patients with diabetes

Association between remnant cholesterol and the risk of cardiovascular disease in Chinese population

The Effects of Calculated Remnant-Like Particle Cholesterol on Incident Cardiovascular Disease: Insights from a General Chinese Population

The Association Between Time-Weighted Remnant Cholesterol and Cardiovascular and Non-Cardiovascular Mortality: A Population-Based Cohort Study

Remnant cholesterol and risk of major adverse cardiovascular events: a systematic review and dose–response meta-analysis of cohort studies

The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes

The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction

Cumulative Remnant Cholesterol as a causal risk factor for Ischemic Heart Disease: A Prospective Cohort Study

Investigating the impact of remnant cholesterol on new-onset stroke across diverse inflammation levels: Insights from the China Health and Retirement Longitudinal Study (CHARLS)